26670 The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in a baricitinib phase 3 study, BREEZE-AD5

Abstract

BREEZE-AD5 (NCT03435081), a placebo (PBO)-controlled, phase 3, monotherapy trial, demonstrated the safety and efficacy of baricitinib (BARI), an oral selective Janus kinase 1/2 (JAK1/JAK2) inhibitor, for the treatment of moderate-to-severe atopic dermatitis in US and Canadian adults with previously inadequate or intolerable responses to topical therapy. This post hoc, multiple mediator analysis of BREEZE-AD5 analyzed whether improvement in itch (measured by the change from baseline in a numeric rating scale) or in skin severity (measured by the change from baseline in Eczema Area and Severity Index [EASI] or in Body Surface Area [BSA]) mediated the treatment effect over PBO on changes in the Dermatology Life Quality Index (DLQI).